Montreal, June 18, 2014 – AmorChem partners with Dr. Przemyslaw (Mike) Sapieha (Hôpital Maisonneuve-Rosemont) and Univalor to discover new drugs for the treatment of diabetic macular edema. Dr. Sapieha has been working for a number of years on a novel target Semaphorin 3A (SEMA 3A) and its role in ocular diseases and has discovered therapeutics which may be useful in treating and stopping the development of the disease. Read the News Release.

In conducting its shareholders’ meeting on January 27, Univalor concluded the process of disclosing its results for 2012–13. Our accomplishements allow us to begin 2014 with enthusiasm and confidence.

By Johanne Bissonnette

Toward a cure against myotonic dystrophy type 1: When the planets are aligned

Small markets, high costs of research, uncertainty related to treatment reimbursement: several factors combine to curb the development of orphan drugs. Nevertheless, at the Université de Montréal, Dr. Pascal Chartrand’s work to develop a treatment for myotonic dystrophy type 1—a rare disease that affects one in 10,000 people worldwide—has attracted the interest of investors and the pharmaceutical industry. For people with this terrible disease, the planets do seem to be aligned in finding a cure. Here’s a closer look at a project in which all factors for success are coming together.


How to finance and grow a business coming from academic research ?

Friday, February 28, 2014 from noon to 2 P.M. (A lunch will be served)
Université de Montréal, Pavillon André-Aisenstadt, Room 1360

This event will be held in French.

Sign up for free before February 26, 2014 !


How to move from student to entrepreneur ?

Polytechnique Montréal, Pavillon Lassonde - M1020
Thursday, March 27, 2014 from 12:30 P.M. to 1:30 P.M. (Lunch will be served)

This event will be held in french.

Sign up for free before March 25, 2014 !